Search results for "Migraine treatment"

showing 7 items of 7 documents

Triptans and CGRP blockade - impact on the cranial vasculature.

2017

Abstract The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and mig…

0301 basic medicineMigraine DisordersCalcitonin gene related peptide – CGRPNeuropeptidelcsh:MedicineMigraine modelsReviewTriptansReview ArticleCalcitonin gene-related peptide03 medical and health sciences0302 clinical medicineJournal ArticlemedicineHumansMigraine treatmentReceptorbusiness.industryTriptans Calcitonin gene related peptide – CGRP Anti-CGRP (receptor) monoclonal antibodies – mAbs Middle meningeal artery Middle cerebral arteries Migraine models Magnetic resonance angiography (MRA)Anti-CGRP (receptor) monoclonal antibodies – mAbsTrigeminovascular systemlcsh:RTriptansGeneral MedicineMiddle meningeal arterymedicine.diseaseTryptamines3. Good healthMagnetic resonance angiography (MRA)Middle cerebral arteries030104 developmental biologyAnesthesiology and Pain MedicineMigraineAnesthesiaNeurology (clinical)SerotoninbusinessNeuroscience030217 neurology & neurosurgerymedicine.drugReceptors Calcitonin Gene-Related PeptideThe journal of headache and pain
researchProduct

PACAP38 and PAC1 receptor blockade: a new target for headache?

2018

Abstract Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. Moreover, PACAP38 is a potent inducer of migraine-like attacks, but the mechanism behind this has not been fully elucidated. Migraine is a neurovascular disorder, recognized as the second most disabling disease. Nevertheless, the antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are the only prophylactic treatment developed specifically for migraine. These antibodies have displayed positive results in clinical trials, but are not effective for all patients; therefore, new pharmacol…

0301 basic medicineSide effectPAC1 receptorMigraine DisordersMigraine Disorders/drug therapylcsh:MedicinePituitary Adenylate Cyclase-Activating Polypeptide/antagonists & inhibitorsReview ArticleTriptansPharmacologyCalcitonin gene-related peptidePACAPNeuroprotectionmigraine; PAC1 receptor; PACAP; prophylactic treatment; animals; disease models animal; headache; humans; migraine disorders; pituitary adenylate cyclase-activating polypeptide; receptors pituitary adenylate cyclase-activating polypeptide type I; neurology (clinical); anesthesiology and pain medicine03 medical and health sciences0302 clinical medicineAnimalsHumansMedicineMigraine treatmentReceptorMigraineHeadache/drug therapybusiness.industrylcsh:RHeadacheGeneral Medicinemedicine.disease3. Good healthBlockadeDisease Models Animal030104 developmental biologyAnesthesiology and Pain MedicineMigrainePituitary Adenylate Cyclase-Activating PolypeptideNeurology (clinical)businessProphylactic treatment030217 neurology & neurosurgeryReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type IReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type I/antagonists & inhibitorsmedicine.drugJournal of Headache and Pain
researchProduct

Validity and reliability of the Migraine-Treatment Optimization Questionnaire.

2009

Our aim was to establish the validity and reliability of a patient-rated Migraine Treatment Optimization Questionnaire (M-TOQ in primary care. Patients who met International Classification of Headache Disorders, 2nd edn criteria for migraine completed a 19-item questionnaire containing candidate items for the M-TOQ and three questionnaires designed to test convergent/construct validity [Migraine Disability Assessment Scale (MIDAS), Headache Impact Test (HIT)-6 and Migraine-Specific Quality of Life Scale (MSSQoL)]. A 15-item (M-TOQ15) and a five-item (M-TOQ-5) questionnaire were derived. Two hundred and fifty-three adult patients were recruited. Five treatment optimization domains were iden…

AdultMalemedicine.medical_specialtyMigraine DisordersValidityDisability EvaluationQuality of lifeCronbach's alphaSurveys and QuestionnairesOutcome Assessment Health CareMedicineHumansMigraine treatmentAgedbusiness.industryConstruct validityReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseaseTolerabilityMigrainePhysical therapyQuality of LifeInternational Classification of Headache DisordersFemaleNeurology (clinical)businessClinical psychologyCephalalgia : an international journal of headache
researchProduct

Effect of chemical enhancers on the in vitro percutaneous absorption of sumatriptan succinate

2005

The effects of percutaneous enhancers on the transdermal absorption of sumatriptan succinate were investigated by in vitro permeation studies. Pretreatment of porcine skin with ethanol (vehicle), polyethylene glycol 600, Span 20, oleic acid, R-(+)-limonene, alpha-bisabolol and 1,8-cineole (at 5% in ethanol, w/w) produced in all cases an increase in the flux of sumatriptan. The amount of sumatriptan retained in the skin was also determined. Ethanol has showed a low but significant increment on the drug transdermal flux. Treatment of the skin with alpha-bisabolol shows the same enhancer effect than ethanol. Span 20, oleic acid, and polyethylene glycol 600 have shown a moderate enhancing activ…

SwineSkin AbsorptionPharmaceutical SciencePolyethylene glycolIn Vitro TechniquesPharmacologyAdministration CutaneousDiffusionchemistry.chemical_compoundSumatriptan SuccinatemedicineAnimalsMigraine treatmentSkinTransdermalEthanolChromatographySumatriptanGeneral Medicinemusculoskeletal systemSumatriptanOleic acidchemistrySolventscardiovascular systemFlux (metabolism)Biotechnologymedicine.drugEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Eficacia de la terapia manual articulatoria vertebral en pacientes con migraña

2019

La migraña es uno de los trastornos del sistema nervioso más comunes y se considera la tercera causa de incapacidad en el mundo en menores de 50 años. El tratamiento de la migraña mediante terapia manual articulatoria vertebral (TMAV) puede ser efectivo, sin embargo, existe más controversia que en otros tipos de cefaleas. El objetivo del presente estudio es valorar los cambios producidos tras la aplicación de TMAV en pacientes con migraña en cuanto a la intensidad del dolor y su impacto.44 participantes con una edad media de 39 años (desviación típica= 9.47) con migraña, fueron divididos en dos grupos de forma aleatoria: 1) grupo TMAV (n=22), 2) grupo control (n=22). Se realizaron dos evalu…

lcsh:R5-920FisioteràpiaVisual analogue scalebusiness.industryHeadache impactMean agemedicine.diseaseMigraineAnesthesiamedicineIn patientMigraine treatmentHeadachesmedicine.symptombusinesslcsh:Medicine (General)
researchProduct

Multifocal Repetitive Transcranial Magnetic Stimulation—A Novel Paradigm in Migraine Treatment

2019

Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation method used for analyzing structural and functional interactions in brain, assess cortical reactivity, and map functionally relevant brain regions inducing a controlled current pulse in a defined region of the cortex. From a clinical point of view, TMS has shown promising results in the therapeutic approach in a large number of psychiatric and neurological conditions such as anxiety, depression, OCD, headache disorders—migraine being one of the most encountered, etc. In patients with migraine, the pharmacologic therapy can be divided in abortive and preventive treatment of the attack. Usually the treatment is starte…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentStimulationmedicine.diseaseTranscranial magnetic stimulationTherapeutic approachPhysical medicine and rehabilitationMigraineBrain stimulationmedicineAnxietyMigraine treatmentmedicine.symptombusinessDepression (differential diagnoses)
researchProduct

Noninvasive neurostimulation methods for migraine therapy: The available evidence.

2016

Background Migraine is one of the most disabling neurological disorders. The current pharmacological armamentarium is not satisfying for a large proportion of patients because the responder rate does not exceed 50% on average and the most effective drugs often induce intolerable side effects. During recent years, noninvasive central and peripheral neuromodulation methods have been explored for migraine treatment. Overview A review of the available evidence suggests that noninvasive neuromodulation techniques could be beneficial for migraine patients. The transcranial stimulation methods allow modulating selectively cortical activity and can thus be curtailed to the patient’s pathophysiologi…

vagus nervesneurology (clinical)orbital stimulationmedicine.medical_specialtymedicine.medical_treatmentMigraine DisordersTranscranial Direct Current Stimulation03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationmedicineHumans030212 general & internal medicineMigraine treatmentDeep transcranial magnetic stimulationNeurostimulationtranscranial direct current stimulation; transcranial magnetic stimulation; transcutaneous suprave stimulation; evidence-based medicine; humans; migraine disorders; transcranial direct current stimulation; transcranial magnetic stimulation; transcutaneous electric nerve stimulation; treatment outcome; neurology (clinical)orbital stimulation; vagus nervesEvidence-Based MedicineTranscranial direct-current stimulationbusiness.industryGeneral Medicinemedicine.diseaseTranscranial Magnetic StimulationNeuromodulation (medicine)Transcranial magnetic stimulationTreatment OutcomeMigraineAnesthesiaTranscutaneous Electric Nerve StimulationNeurology (clinical)business030217 neurology & neurosurgeryVagus nerve stimulationtranscutaneous suprave stimulationCephalalgia : an international journal of headache
researchProduct